Skip to main content
SpringerLink
Log in

Risiken einer Langzeitgabe von Neuroleptika

  • Chapter
Schizophrene erkennen, verstehen, behandeln

Part of the book series: Aktuelle Probleme der Schizophrenie ((SCHIZOPHRENIE,volume 1))

  • 31 Accesses

Zusammenfassung

Der vorliegende Artikel gibt einen Überblick über Indikationen und über praxisrelevante Nebenwirkungen einer Neuroleptikalangzeitgabe. Gewichtsveränderungen, sexuelle Funktionsstörungen, depressive Zustandsbilder sowie Spätdyskinesien (“late movement disorders”) werden ausführlich diskutiert. Auch auf seltene und unregelmäßig auftretende Nebenwirkungen auf Auge, Darm und Haut sowie auf das maligne neuroleptische Syndrom und mögliche Absetzeffekte der Neuroleptika wird kurz eingegangen.

Summary

Risks of long-term neuroleptic treatment. This article presents an overview of recent research on adverse effects of long-term neuroleptic treatment. Side effects such as weight changes, sexual dysfunctions, depressive symptoms and late movement disorders are discussed in detail.

Idiosyncratic side effects on eyes, bowels and skin as well as the neuroleptic malignant syndrome and neuroleptic withdrawal symptoms are described briefly.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abbott RJ, Loizon LA (1986) Neuroleptic malignant syndrome. Br J Psychiatry 148: 47–51

    Article  PubMed  CAS  Google Scholar 

  2. Alarcon de R, Carney MWP (1969) Severe depressive mood changes following slow-release intramuscular fluphenazine injection. Br Med J 3: 564–567

    Article  PubMed  Google Scholar 

  3. Ananth J, Ghadirian A (1980) Drug-induced mood disorder. Int Pharmacopsychiatry 15: 58–73

    Google Scholar 

  4. Blair JH, Simpson GM (1966) Effects of antipsychotic drugs on reproductive functions. Dis Nerv Syst 27: 645–647

    PubMed  CAS  Google Scholar 

  5. Cheuny HK (1981) Schizophrenics fully remitted on neuroleptic for 3–5 years to stop or continue drugs. Br J Psychiatry 138: 490–494

    Article  Google Scholar 

  6. Cookson JC (1988) A UK multicenter weight-change study on the effects of depot antipsychotic medication in chronic schizophrenic patients, with computerised data transfer (Abstract). Psychophar- macology 96: 257

    Google Scholar 

  7. Crow TJ, Owens DGC, Johnstone EC, Cross AJ, Owen F (1984) Gibt es Spätdyskinesien? In: Kryspin-Exner K, et al (Hrsg) Langzeittherapie psychiatrischer Erkrankungen. Schattauer, Stuttgart New York

    Google Scholar 

  8. Davis J, Janicak P, Linden R, Moloney J, Pavkovic I (1983) Neuroleptics and psychotic disorders. In: Coyle JT, et al (eds) Neurochemical, behavioral and clinical perspectives. Raven Press, New York

    Google Scholar 

  9. De Long, Poley BJ, McFarlane JR (1965) Ocular changes associated with long term chlorpromazine therapy. Arch Ophthalmol 73: 611

    Article  Google Scholar 

  10. Dilsaver SC, Alessi NE (1988) Antipsychotic withdrawal symptoms: phenomenology and pathophysiology. Acta Psychiatr Scand 77: 241–246

    Article  PubMed  CAS  Google Scholar 

  11. Doss FW (1979) The effects of antipsychotic drugs on body weight: a retrospective review. J Clin Psychiatry 40: 528/53–530/55

    Google Scholar 

  12. Evans DL, Rogers JF, Peiper SC (1979) Intestinal dilatation associated with phenothiazine therapy: a case report and literature review. Am J Psychiatry 136: 970–972

    PubMed  CAS  Google Scholar 

  13. Fleischhacker WW, Unterweger B, Hinterhuber H (1987) Das maligne neuroleptische Syndrom. In: Pichot P, et al (Hrsg) Neuroleptika, Rückblick 1952–1986, künftige Entwicklungen. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  14. Gaertner HJ (1983) Klinische Pharmakologie der Neuroleptika. In: Langer G, et al (Hrsg) Psychopharmaka, Grundlagen und Therapie. Springer, Wien New York, S 227–250

    Google Scholar 

  15. Gallant DM, Bishop MP, Steele CA (1973) Molindone: a crossover evaluation of capsule and tablet formulations in severely ill schizophrenic patients. Current Therapy Res 15: 915–918

    CAS  Google Scholar 

  16. Gardos G, Cole JO (1976) Maintenance antipsychotic therapy: is the cure worse than the disease? Am J Psychiatry 133: 32–36

    PubMed  CAS  Google Scholar 

  17. Gerlach J, Casey DE (1988) Tardive dyskinesia. Acta Psychiatr Scand 77: 369–378

    Article  PubMed  CAS  Google Scholar 

  18. Ghardirian AM, Chouinard G, Annable L (1982) Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 170: 463

    Article  Google Scholar 

  19. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown C, Silverstone T (1988) A clinical trial of the efficacy and acceptability of D-Fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 153: 208–213

    Article  PubMed  CAS  Google Scholar 

  20. Hanson D (1988) Causes and consequences of late onset involuntary motor movements in schizophrenic patients. Current Opinion in Psychiatry 1: 32–40

    Article  Google Scholar 

  21. Hartmann W (1987) Neuroleptikabedingte pharmakogene Depression. In: Pichot P, et al (Hrsg) Neuroleptika, Rückschau 1952–1986, künftige Entwicklungen. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  22. Hogarty GE, Ulrich RF, Mussare F, Aristigneta N (1977) Drug discontinuation among long-term, successfully mantained schizophrenic outpatients. Dis Nerv Syst 37: 494–500

    Google Scholar 

  23. Jeste DV, Wyat RJ (1981) Changing epidemiology of tardive dyskinesia: a overview. Am J Psychiatry 138: 297–309

    Article  PubMed  CAS  Google Scholar 

  24. Johnson DAW, Breen M (1979) Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatr Scand 59: 525–528

    Google Scholar 

  25. Johnson DAW (1988) The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 152: 320–323

    Article  PubMed  CAS  Google Scholar 

  26. Kane JM, Smith JM (1982) Tardive dyskinesia. Arch Gen Psychiatry 39: 473–481

    Article  PubMed  CAS  Google Scholar 

  27. Kemeny MM, Martin EC, Lane FC, Stillman RM (1980) Abdominal distention and aortic obstruction associated with phenothiazines. JAMA 243: 683–684

    Article  PubMed  CAS  Google Scholar 

  28. Knights A, Hirsch SR (1981) “Revealed” depression and drug treatment for schizophrenia. Arch Gen Psychiatry 38: 806–811

    Google Scholar 

  29. Korsgaard S, Skausig OB (1979) Increase in weight after treatment with depot neuroleptics. Acta Psychiatr Scand 59: 139–144

    Article  PubMed  CAS  Google Scholar 

  30. Kotin J, Wilbert DE, Verbug D, et al (1976) Thioridazine and sexual dysfunction. Am J Psychiatry 133: 82–85

    PubMed  CAS  Google Scholar 

  31. Leblhuber F, Reisecker F, Bengesser G (1987) Tiaprid in der Behandlung irreversibler tardiver Dyskinesien — erste Erfahrungen. Z Gerontol 20: 49–51

    PubMed  CAS  Google Scholar 

  32. Livingston MG (1988) Weight changes in schizophrenic patients receiving antipsychotic medication (Abstract). Psychopharmacology 96: 257

    Google Scholar 

  33. Mitchell JE, Popkin MK (1982) Antipsychotic drug therapy and sexual dysfunction in men. Am J Psychiatry 139: 633–637

    PubMed  CAS  Google Scholar 

  34. Modestin J (1983) 30 Jahre Neuroleptika - Zeit zur kritischen Auseinandersetzung. Dtsch Med Wochenschr 108: 1446–1451

    Google Scholar 

  35. Möller HJ (1987) Indikation und Differentialindikation der neuroleptischen Langzeitmedikation. In: Pichot P, et al (Hrsg) Neuroleptika, Rückschau 1952–1986, künftige Entwicklungen. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  36. Müller P (1981) Depressive Syndrome im Verlauf schizophrener Psychosen. In: Glatzel J, et al (Hrsg) Forum der Psychiatrie. Enke, Stuttgart

    Google Scholar 

  37. National University of Malaysia, Kuala Lumpur, Malaysia (1988) Long-term phenothiazine administration and the eye in 100 malay- sians. Br J Psychiatry 152: 278–280

    Article  Google Scholar 

  38. Nestoros JN, Lehmann HE (1979) Neuroleptics and male sexual dysfunction. International Drug Therapy Newsletter 14: 21–24

    Google Scholar 

  39. Poser S, Poser W (1983) Toxische Wirkungen von Arzneimitteln auf das Zentralnervensystem. Nervenarzt 54: 612–623

    Google Scholar 

  40. Ayd FJ (1982) Psychotropic drugs and female sexual dysfunction. International Drug Therapy Newsletter 17: 37–39

    Google Scholar 

  41. Putten T van, May PRA (1978) “Akinetic depression” in schizophrenia. Arch Gen Psychiatry 35: 1101–1107

    Google Scholar 

  42. Rifkin A, Siris SG (1986) Zum heutigen Erkenntnisstand der Problematik: Depression bei der Schizophrenie. In: Hinterhuber H, et al (Hrsg) Seiteneffekte und Störwirkungen der Psychopharmaka. Schattauer, Stuttgart New York

    Google Scholar 

  43. Roy A (1984) Do neuroleptics cause depression? Biol Psychiatry 19: 777–781

    PubMed  CAS  Google Scholar 

  44. Rüther E, Haag M, Oefele K von, Keppler E, Haag H (1987) Späte extrapyramidale Hyperkinesen (Spätdyskinesien): Risiko der Neuro- lepsie? In: Pichot P, et al (Hrsg) Neuroleptika, Rückschau 1952–1986, künftige Entwicklungen. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  45. Silverstone T, Smith G, Goodall E (1988) Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 153: 214–217

    Article  PubMed  CAS  Google Scholar 

  46. Simpson GM, Amin M, Konz E (1965) Withdrawal effects of phe- nothiazines. Compr Psychiatry 6: 347–351

    Article  PubMed  CAS  Google Scholar 

  47. Spieß-Kiefer C (1985) Malignes neuroleptisches Syndrom: diagnostische und therapeutische Probleme. Diagnostik 18: 30–35

    Google Scholar 

  48. Thomas P, McGuire R (1986) Orofacial dyskinesia, cognitive function and medication. Br J Psychiatry 149: 216–220

    Article  PubMed  CAS  Google Scholar 

  49. Thum G (1972) Nebenwirkungen verschiedener Medikamente am Auge. Fortschritte der Medizin 90: 624–628

    Google Scholar 

  50. Waddington JL, Youssef HA (1986) An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms. Am J Psychiatry 143: 1162–1165

    PubMed  CAS  Google Scholar 

  51. Waddington JL, Youssef HA (1988) Tardive dyskinesia in bipolar affective disorder: aging, cognitive dysfunction, course of illness, and exposure to neuroleptica and lithium. Am J Psychiatry 145: 613–616

    PubMed  CAS  Google Scholar 

  52. Wheeler RH, Bhalero VR, Winkleman NW (1968) Ocular pigmentation, extrapyramidal symptoms and phenothiazine dosage. Br J Psychiatry 115: 683–690

    Google Scholar 

  53. Wistedt B, Palmstierna T (1983) Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics. J Clin Psychiatry 44: 369–371

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatrische Universitätsklinik, Währinger Gürtel 18-20, A-1090, Wien, Österreich

    Dr. Martina de Zwaan & G. Schönbeck

Authors
  1. Dr. Martina de Zwaan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Schönbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Wien, Austria

    G. Schönbeck

  2. Klagenfurt, Austria

    T. Platz

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag/Wien

About this chapter

Cite this chapter

de Zwaan, M., Schönbeck, G. (1990). Risiken einer Langzeitgabe von Neuroleptika. In: Schönbeck, G., Platz, T. (eds) Schizophrene erkennen, verstehen, behandeln. Aktuelle Probleme der Schizophrenie, vol 1. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9089-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-9089-0_9

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82208-1

  • Online ISBN: 978-3-7091-9089-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation